| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d59cca7f9fa4d79747ceb46ae632cb8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09c4bf4ee20e690fc1b990ceb5d27765 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be2ea89f1bb6b54f5056690c5bfcc113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_062d1a60844a9c752bb3c2a8ce74b5de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa8283a2755b4f0354a774cd204506d2 |
| publicationDate |
2022-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114949199-A |
| titleOfInvention |
A sugar-modified manganese-based nanoadjuvant, manganese-based nanovaccine, and preparation method and application thereof |
| abstract |
The invention relates to a sugar-modified manganese-based nano-adjuvant, a manganese-based nano-vaccine and a preparation method and application thereof. The sugar-modified manganese-based nano-adjuvant comprises a manganese phosphate core and a surface modified with mannose and has a positive charge phospholipid bilayer shell. The manganese-based nano-adjuvant can effectively adsorb immune antigens; it can effectively deliver immune antigens to antigen-presenting cells, greatly enhance the uptake of immune antigens by antigen-presenting cells, and target and improve the tumor microenvironment, thereby efficiently activating immune cells , by using a lower dose to obtain more excellent immunotherapy effect when adsorbing less antigen. |
| priorityDate |
2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |